Gadolinium chelate toxicity in renal failure;Toxicités des chélates de gadolinium chez le patient insuffisant rénal

Sang Thrombose Vaisseaux

Volumn 22, Issue 2, 2010, Pages 90-95

  Ledneva, E ^a   Janus, N ^a   Amet, S ^a   Launay Vacher, V ^a   Deray, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Gadolinium chelates; Nephrogenic systemic fibrosis; Renal insufficiency

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE;

DRUG TOLERANCE; HUMAN; KIDNEY FAILURE; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; SHORT SURVEY;

EID: 77949684624     PISSN: 09997385     EISSN: 19506104     Source Type: Journal    
DOI: 10.1684/stv.2009.0455     Document Type: Short Survey

References (36)

1. Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 2009 ; 250 : 618-28.
2. Thomsen HS, Almen T, Morcos SK. Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 2002 ; 12 : 2600-5.
3. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000 ; 356 : 1000-1.
4. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008 ; 66 : 230-4.
5. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006 ; 21 : 1104-8.
6. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006 ; 17 : 2359-62.
7. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008 ; 43 : 141-4.
8. Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the finest study. Eur J Radiol 2009.
9. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006 ; 20 : 563-76.
10. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 2007 ; 20 : 179-85.
11. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol 2006 ; 60 : 314-23.
12. Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999 ; 34 : 443-8.
13. Swan SK, Baker JF, Free R, et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 1999 ; 9 : 317-21.
14. Morcos SK, Thomsen HS. European society of urogenital radiology guidelines on administering contrast media. Abdom Imaging 2003 ; 28 : 187-90.
15. Tombach B, Bremer C, Reimer P, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 2001 ; 218 : 651-7.
16. Rieger J, Sitter T, Toepfer M, Linsenmaier U, Pfeifer KJ, Schiffl H. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 2002 ; 17 : 824-8.
17. Sam 2nd AD, Morasch MD, Collins J, Song G, Chen R, Pereles FS. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 2003 ; 38 : 313-8.
18. Ergun I, Keven K, Uruc I, et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 2006 ; 21 : 697-700.
19. Thomsen HS. Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 2004 ; 14 : 1654-6.
20. Briguori C, Colombo A, Airoldi F, et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 2006 ; 67 : 175-80.
21. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006 ; 16 : 2619-21.
22. Thomsen HS, Morcos SK, Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 2006 ; 61 : 905-6.
23. Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006 ; 54 (2 Suppl.) : S31-S4.
24. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001 ; 23 : 383-93.
25. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003 ; 139 : 903-6.
26. Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005 ; 46 : 763-5.
27. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007 ; 22 : 3174-8.
28. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007 ; 243 : 148-57.
29. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007 ; 56 : 21-6.
30. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007 ; 56 : 21-6.
31. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007 ; 242 : 647-9.
32. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2007 ; 2 : 200-2.
33. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006 ; 145 : 234-5.
34. Thomsen HS. European society of urogenital radiology guidelines on contrast media application. Curr Opin Urol 2007 ; 17 : 70-6.
35. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007 ; 80 : 73-6.
36. Thomsen HS. How to avoid CIN: guidelines from the european society of urogenital radiology. Nephrol Dial Transplant 2005 ; 20 (Suppl. 1) : i18-i22.